KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Medpace Holdings (MEDP) Non Operating Income (2016 - 2026)

Medpace Holdings filings provide 12 years of Non Operating Income readings, the most recent being $6.1 million for Q1 2026.

  • On a quarterly basis, Non Operating Income rose 31.01% to $6.1 million in Q1 2026 year-over-year; TTM through Mar 2026 was $16.4 million, a 226.31% increase, with the full-year FY2025 number at $7.4 million, up 83.48% from a year prior.
  • Non Operating Income hit $6.1 million in Q1 2026 for Medpace Holdings, down from $12.6 million in the prior quarter.
  • In the past five years, Non Operating Income ranged from a high of $12.6 million in Q4 2025 to a low of -$16.5 million in Q4 2024.
  • Median Non Operating Income over the past 5 years was -$133000.0 (2024), compared with a mean of $821352.9.
  • Biggest five-year swings in Non Operating Income: surged 5107.47% in 2024 and later crashed 1251.13% in 2025.
  • Medpace Holdings' Non Operating Income stood at -$2.8 million in 2022, then soared by 155.38% to $1.5 million in 2023, then tumbled by 1168.83% to -$16.5 million in 2024, then skyrocketed by 176.53% to $12.6 million in 2025, then tumbled by 51.77% to $6.1 million in 2026.
  • The last three reported values for Non Operating Income were $6.1 million (Q1 2026), $12.6 million (Q4 2025), and -$489000.0 (Q3 2025) per Business Quant data.